19+ International Experts from Industry, Academia and National Biobanks

  • United States Minor OutlyingAmelia Warner
    Head of Clinical Pharmacogenetics
    Merck and the I-PWG
  • Xavier Briand
    Team Leader, Biobank
    Novartis
  • FranceAnne Bahr
    Deputy R&D and Data Privacy Officer
    sanofi-aventis
  • G.-Dagher-4 Georges Dagher
    Deputy Director, Clinical Research
    INSERM and Leader of Funding & Financing at BBMRI

Biobanking, Biomarkers and Bioethics: Establishing Partnerships and Improving Biobanking to Further Medical Research

With the multitude of practical, ethical and regulatory considerations that must be taken into account by anyone setting-up or running a biobank mean that it is often difficult to keep abreast of the latest developments in the field.

With representation from a wide range of major pharmaceutical companies including AstraZeneca, Merck, Novartis, Sanofi-Aventis, Bayer, Shire and Roche to name a few, as well as keynote presentations from internationally-recognised thought leaders from academia and national biobanks, this promises to be an event not-to-be-missed!

Now in it’s 4th Year Global Biobanking has welcomed over 200 Attendees from over 140 different organisations.


Join us in London on September 27th – 29th 2011 to learn and discuss how to:

  • Improve sample storage capabilities and quality through collaboration with new expertise from Frans van der Horst, Chair, Dutch Collaborative Biobank and Georges Dagher of INSERM and the BBMRI
  • Enable greater sharing of data and specimens and improve biomarker research by establishing international biobanking standards and procedures with insights from Kim Myers, Director, U.S. National Cancer Institute
  • Establish, develop and maintain an efficient global biobanking network with new case studies from Xavier Briand, Team Leader, Biobank, Novartis and Delphine Lagarde, Head of Basel Sample Repository, Roche
  • Successfully Navigating the Bioethical Complexities and Constraints of Sample Collection and Management with examples and experiences from international bioethics experts Dr. Nik Zeps, Prof. Ruth Chadwick and Prof. Bartha Knoppers
  • Increase the effectiveness of medical and biomarker research by improving sample quality through careful sourcing and management; discussions led by Bayer, AstraZeneca and Merck

New and Exclusive for 2011 – Biomarkers & Personalised Healthcare Focus Day

Effective biomarker research is not only key to better medical development but also the gateway to personalised healthcare. That’s why this year’s event brings you:

  • 5 exclusive plenary sessions dedicated to biomarkers & personalised healthcare
  • An open panel discussion with the day’s international Speaker faculty
  • Networking opportunities with peers and experts in this important field

Testimonial from 2010

The line-up of excellent speakers brought out two days of highly scientific and educational presentations and interactive discussions… There was sufficient time for networking with colleagues and interaction with vendors and sponsors. This conference has proven that next year’s IQPC Global Biobanking will be an event not to miss.
Bas de Jong, ISBER and Erasmus MC Tissue Bank, after Global Biobanking 2010


video-Gerd-Maass

Biobanking at Roche - Interview with Gerd Maass, VP for R&D at Roche Pharmaceuticals

With a focus on biobanking Maass outlines some common difficulties in isolating biomarkers from samples that have previously been stored in a bio/tissue bank; he shares his opinions on storage techniques for samples to get the best results. He also sheds light on the state of Roche’s internal biobank, discusses the extent to which Roche sources samples externally from biobanks, and the main difficulties/challenges with this. Finally, he gives some research-side advice for new or expanding biobanks.

2011 Sponsors and Exhibitors Media Partners
_fsponsor media

[ Register Now ]